AbbVie Revenue 2012-2026 | ABBV
AbbVie annual/quarterly revenue history and growth rate from 2012 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- AbbVie revenue for the quarter ending March 31, 2026 was $15.002B, a 12.43% increase year-over-year.
- AbbVie revenue for the twelve months ending March 31, 2026 was $62.819B, a 9.5% increase year-over-year.
- AbbVie annual revenue for 2025 was $61.16B, a 8.57% increase from 2024.
- AbbVie annual revenue for 2024 was $56.334B, a 3.71% increase from 2023.
- AbbVie annual revenue for 2023 was $54.318B, a 6.44% decline from 2022.
|
AbbVie Annual Revenue (Millions of US $) |
|
|---|---|
| 2025 | $61,160 |
| 2024 | $56,334 |
| 2023 | $54,318 |
| 2022 | $58,054 |
| 2021 | $56,197 |
| 2020 | $45,804 |
| 2019 | $33,266 |
| 2018 | $32,753 |
| 2017 | $28,216 |
| 2016 | $25,638 |
| 2015 | $22,859 |
| 2014 | $19,960 |
| 2013 | $18,790 |
| 2012 | $18,380 |
| 2011 | $17,444 |
|
AbbVie Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2026-03-31 | $15,002 |
| 2025-12-31 | $16,618 |
| 2025-09-30 | $15,776 |
| 2025-06-30 | $15,423 |
| 2025-03-31 | $13,343 |
| 2024-12-31 | $15,102 |
| 2024-09-30 | $14,460 |
| 2024-06-30 | $14,462 |
| 2024-03-31 | $12,310 |
| 2023-12-31 | $14,301 |
| 2023-09-30 | $13,927 |
| 2023-06-30 | $13,865 |
| 2023-03-31 | $12,225 |
| 2022-12-31 | $15,121 |
| 2022-09-30 | $14,812 |
| 2022-06-30 | $14,583 |
| 2022-03-31 | $13,538 |
| 2021-12-31 | $14,886 |
| 2021-09-30 | $14,342 |
| 2021-06-30 | $13,959 |
| 2021-03-31 | $13,010 |
| 2020-12-31 | $13,858 |
| 2020-09-30 | $12,902 |
| 2020-06-30 | $10,425 |
| 2020-03-31 | $8,619 |
| 2019-12-31 | $8,704 |
| 2019-09-30 | $8,479 |
| 2019-06-30 | $8,255 |
| 2019-03-31 | $7,828 |
| 2018-12-31 | $8,305 |
| 2018-09-30 | $8,236 |
| 2018-06-30 | $8,278 |
| 2018-03-31 | $7,934 |
| 2017-12-31 | $7,739 |
| 2017-09-30 | $6,995 |
| 2017-06-30 | $6,944 |
| 2017-03-31 | $6,538 |
| 2016-12-31 | $6,796 |
| 2016-09-30 | $6,432 |
| 2016-06-30 | $6,452 |
| 2016-03-31 | $5,958 |
| 2015-12-31 | $6,400 |
| 2015-09-30 | $5,944 |
| 2015-06-30 | $5,475 |
| 2015-03-31 | $5,040 |
| 2014-12-31 | $5,452 |
| 2014-09-30 | $5,019 |
| 2014-06-30 | $4,926 |
| 2014-03-31 | $4,563 |
| 2013-12-31 | $5,111 |
| 2013-09-30 | $4,658 |
| 2013-06-30 | $4,692 |
| 2013-03-31 | $4,329 |
| 2012-12-31 | $5,206 |
| 2012-09-30 | $4,508 |
| 2012-06-30 | $4,493 |
| 2012-03-31 | $4,173 |
| 2011-12-31 | $4,864 |
| 2011-09-30 | $4,409 |
| 2011-06-30 | $4,274 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $367.673B | $61.160B |
| AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |